NOXtec Development Srl.
Nippon Sanso Italia and NOXtec Development Srl. have joined forces to develop and stregthen a company dedicated to design, produce and distribute state-of-the-art medical devices worlwide.
We provide comprehensive delivery and monitoring systems designed to support administration of inhaled nitric oxide in intensive care and acute care environments. Helping hospitals deliver precise therapy, maintain patient safety, and simplify clinical workflows.
The joint venture combines NOXtec Development’s high -level expertise in the development of new high-tech medical products with Nippon Sanso’s 100 years of experience in the production of medical gases.
The goal is to explore new geographies and create social value through innovative solutions. This partnership aims at the technological improvement of devices used in inhaled nitric oxide therapies, thanks to a continuous exchange of information with university and hopital structures , in order to improve their effectiveness and evaluate the development of new applications.
Nitric Oxide Therapy
The nitric oxide therapy market has grown exponentially in recent years, concentrating first in neonatal intensive care units, then in pediatric and adult settings, and finally playing a key role during the last 2 years in the treatment of Covid-19 patients.
The increased use of nitric oxide, a powerful vasodilator, is linked not only to its effectiveness in terms of therapy response times, but above all to its localized action in the cardiopulmonary area, lowering blood pressure rapidly and avoiding interactions with other areas of the human body.
The first device for inhaled nitric oxide therapies, developed by NOXtec Development, has made it possible not only to monitor and manage the therapy in constant doses as the patient’s respiratory flow changes, but also to improve the safe management of the device through remote control systems and automatic calibration.